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Abstract 
An expedient, palladium-mediated cross-coupling approach to functionalize the benzimidazole-based core 
under microwave-assisted conditions has been developed and is described. This protocol, which incorporates 
appendage diversity on this potential scaffold, is found to be compatible with a wide range of electronically- 
and sterically-divergent (hetero)aryl boronic acids. The use of the PdCl2/(SPhos) catalytic system allows the 
formation of a stable and highly active LPd(0) species which was found to be critical for the successful 
synthesis of these novel, pharmacologically-relevant molecules. 
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Introduction 
 
Developing efficient synthetic protocols to access and functionalize an extensive range of structurally diverse 
aryl/heteroaryl scaffolds continues to play a significant role in the area of organic synthesis.1 This late- stage 
diversification, which incorporates appendage diversity into the molecule, plays a vital role in optimizing the 
properties of potential drug candidates. Among the methodologies developed, palladium-mediated synthetic 
protocols play a major role in accessing and functionalizing a wide range of chemical frameworks. Among the 
various metal-mediated reactions, the Suzuki-Miyaura cross-coupling reaction continues to play a vital role as 
evidenced by its usage in many pharmaceutical and academic laboratories.2-7 The mild reaction condition 
makes Suzuki-Miyaura coupling different from other reactions which involve carbon–carbon bond formation.8 
Moreover, this reaction also has other advantages, like high functional-group tolerance, and the commercial 
availability and stability of a wide variety of (hetero)aryl boronic acids. 
Highly functionalized heterocyclic frameworks play a crucial role in medicinal chemistry, material science 
and agrochemical applications. Among heterocyclic systems, the benzimidazole core is found in many 
biologically relevant molecules which requires the functionalization of this framework using palladium- 
mediated cross-coupling reactions.9-16 As a part of our research efforts towards developing protocols that 
incorporate structural diversity into a heteroaromatic system,17-26 we envisioned a Suzuki-Miyaura cross-
coupling methodology to access 2-aryl/heteroaryl-substituted benzimidazoles. In recent years, the use of 
microwave energy in organic synthesis has gained much popularity in both industrial and academic research. 
By employing this efficient source of energy,27-29 compound libraries for lead-compound generation and 
optimization can be performed in a shorter period of time compared to classical thermal methods. By 
employing microwave-accelerated heating,30-32 these reactions can be completed in very short times and with 
excellent yields of the products. The vast amount of literature depicting the vital role of microwave-assisted 
synthesis is well established.33 Accordingly, our studies were focused on the use of microwave energy as an 
efficient energy source for the Suzuki-Miyaura coupling of benzimidazoles. 
 
 
Results and Discussion 
 
The methods of synthesis of benzimidazole include the condensation of 1,2-diaminobenzene with carboxylic 
acid, aldehydes or their derivatives in the presence of strong acids such as hydrochloric acid, polyphosphoric 
acid, p-toluene sulfonic acid, etc. Conversely, the low yields associated with these protocols, and the difficulty 
in isolation of pure products from crude reaction mixtures, increases the demand for more widely applicable 
synthetic methods to functionalize this vital scaffold. The above facts encouraged us to synthesize substituted 
benzimidazoles using a metal-mediated approach. In our new approach, we were interested in developing an 
efficient protocol for the syntheses of 1-(cyclohexyl/cyclopentyl)-2-disubstituted-benzimidazoles utilizing a 
microwave-promoted Suzuki-Miyaura reaction between substituted aryl/heteroaryl boronic acids and the 
common 1-(cyclohexyl/cyclopentyl)-2-iodobenzimidazole intermediates 3a and 3b (Scheme 1).  
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Scheme 1. Synthesis of iodo intermediates 3(a,b) and Suzuki coupling with various boronic acids. 
 
As depicted in Scheme 1, 2-iodo-1-substituted-benzimidazole is the key intermediate for the synthesis of 
the final target molecules 5(a-t). The compounds 2a and 2b were initially prepared by refluxing formic acid 
and cyclopentyl/cyclohexyl-substituted-1,2-diaminobenzene for 20 hours. The intermediate 2-iodo-1-
substituted-benzimidazole compounds 3a and 3b were prepared in good yield by the reaction with t-
butyllithium and N-iodosuccinamide in anhydrous THF. The obtained intermediates, 3a and 3b, were then 
treated with differently substituted aryl/heteroarylboronic acids 4(a-t) using a Suzuki coupling reaction for 
synthesis of the targeted molecules. To optimize the final reaction conditions, a trial reaction was carried out 
with 1-cyclohexyl-2-iodo-1H-benzimidazole (3a) and 4-tolylboronic acid (4b) as the coupling partners. As a part 
of the initial screening, we tried different catalyst-ligand combinations, bases and solvents to get the best yield 
of the final Suzuki-coupled products (Table 1).  
 
Table 1. Screening of different ligands for Suzuki couplinga 
Entry Catalyst Yield 5b (%)b 
1 PdCl2/BINAP 21c 
2 PdCl2/DPPF 37 
3 PdCl2/DPPP 30 
4 PdCl2/SPhos 60 
5 PdCl2/Xantphos 31 
6 PdCl2/A-taphos 45 
aReaction conditions: 3a (1 mmol), 4b (1.6 mmol), 
PdCl2 (5 mol%), Ligand (10 mol%), K2CO3 (2 mmol), 
DMF, microwave heating at 120 ℃ for 30 minutes. 
bGC-MS yield. 
cIsolated yield. 
 
Initially, we carried out the reaction with a palladium chloride catalyst and 2,2′-bis(diphenylphosphino)-
1,1′-binaphthyl (BINAP) ligand in DMF using K2CO3 as base. The reaction mixture was heated at 120 ℃ using a 
microwave synthesizer to obtain the desired product at 21 % final yield following purification using a flash-
column chromatographic technique (Table 1, entry 1). Under this condition, we further screened different 
ligands to identify the suitable catalytic system which may simplify the conversion of the reactant molecules to 
the desired product in good yield (Figure 1). To our delight, we obtained the expected product 5b in 60 % yield 
when 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl (SPhos) was used as the ligand (Table 1, entry 4). 
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Figure 1. Different ligands used for screening for Suzuki coupling. 
 
Our attention was next turned to screening various bases in view of improving the yield of the desired 
product. Accordingly, we screened various organic and inorganic bases using our previous best condition 
(Table 2). Comparing all of the bases used for the synthesis, cesium carbonate was found to be superior and 
more effective towards the catalytic system (Table 2, entry 4). Cesium salts are very versatile in their use in 
organic chemistry due to their large ionic radius, low charge density and, in many of the cases, superiority to 
the analogous potassium compounds. The reason for its unique success is not entirely clear, however, practice 
has proven its applicability. Organic bases and the non-nucleophilic base 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) were also used for our optimization investigation (Table 2: entries 1, 3 and 6). Unfortunately, the 
desired product was obtained in lower yields in all of those screening conditions.  
 
Table 2. Screening of different bases for Suzuki couplinga 
Entry Base Yield 5b (%)b 
1 DABCO 32 
2 K2CO3 60 
3 TEA 20 
4 Cs2CO3 80 
5 K3PO4 40 
6 DBU 30 
7 KOH 5 
aReaction conditions: 3a (1 mmol), 4a (1.6 mmol), PdCl2 (5 
mol%), SPhos (10 mol%), Base (2 mmol), DMF, microwave 
heating at 120 ℃ for 30 minutes. 
bGC-MS yield. 
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We next focused on identifying the suitable solvent system which favors the reaction conditions (Table 3). 
To our delight, we found the formation of the expected product in 95 % (GC-MS yield) with 91 % isolated yield 
when dioxane was used as the solvent (Table 3, entry 6). Finally, the optimized conditions were fixed as 
microwave irradiation of the iodobenzimidazole intermediate 3a and boronic acid in the PdCl2-SPhos catalytic 
system with cesium carbonate as base and dioxane as solvent at 120 ℃.  
 
Table 3. Screening of different solvents for Suzuki couplinga 
Entry Solvent Yield 5b (%)b 
1 Toluene 20 
2 THF 40 
3 DME 30 
4 DCE 50 
5 DMF 80 
6 Dioxane 95 
aReaction conditions: 3a (1 mmol), 4a (1.6 mmol), PdCl2 (5 
mol%), SPhos (10 mol%), Cs2CO3 (2 mmol), solvent, 
microwave heating at 120 ℃ for 30 minutes. 
bGC-MS yield. 
 
After establishing a facile protocol for the Suzuki coupling reaction, we focused our attention on the 
evaluation of the scope of this developed methodology. Accordingly, we treated the intermediates 3a and 3b 
with a variety of boronic acids in our optimized conditions under microwave irradiation. Almost all of the 
reactions were completed within 30-40 minutes. To our delight, we obtained the desired coupled products 
5(a-t) in good to excellent yields. The yield was consistent throughout the substrates irrespective of their 
electronic nature.  
 
Table 4. Scope of Suzuki Coupling reactions with various boronic acids a,b 
 
N
N
N
N
O
   
5a (82 %) b 
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5b (91 %) 
N
N
O
 
5c (90 %) 
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N
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5d (84 %) 
N
N
SO2Et
 
5e (87 %) 
N
N
F
F
 
5f (90 %) 
N
N
N
O
 
5g (81 %) 
N
N
N
N
N
 
5h (90 %) 
N
N
N
N
 
5i (80 %) 
N
N
N
F
 
5j (86 %) 
N
N
CF3
CF3
 
5k (89 %) 
N
N
O
O
 
5l (86 %) 
N
N
CN
F
 
5m (85 %) 
N
N
OCF3
 
5n (90 %) 
N
N
N
 
5o (91 %) 
N
N
N
 
5p (88 %) 
N
N
Cl
 
5q (90 %) 
N
N
N
N
N
 
5r (86 % ) 
N
N
N
N
O
 
5s (90 %) 
N
N
S
 
5t (85 %) 
 
aReaction conditions: 1-Cyclohexy/cyclopentyl-2-iodo-benzimidazole (3a, 3b) (1 mmol), boronic acid 
(1.6 mmol), PdCl2 (5 mol%), SPhos (10 mol%), Cs2CO3 (2 mmol), dioxane, microwave irradiation at 120 
℃ for 30-40 minutes.  bIsolated yield. 
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A plausible mechanism for the Suzuki-Miyaura cross-coupling reaction is as follows: the initially formed, 
coordinative-unsaturated palladium species LPd(0) undergoes oxidative addition with the iodobenzimidazole 
intermediate to form the oxidative adduct complex. Subsequent trans-metalation from the ate-complex of 
boron to the oxidative adduct complex, followed by reductive elimination, yields the cross-coupled product. 
 
 
Conclusions 
 
A different approach for the synthesis of novel 1-substituted-2-(hetero)arylbenzimidazoles in excellent yields 
has been developed under microwave conditions. This method has provided easy access to a diverse range of 
2-(hetero)arylbenzimidazoles of potential medicinal relevance. The protocol is found to be conducive with a 
wide range of electronically and sterically diverse (hetero)arylboronic acids. The use of a PdCl2/SPhos catalytic 
system was found to be influential in pushing these reactions to excellent conversions. 
 
 
Experimental Section 
 
General. All solvents and reagents were obtained from commercial suppliers and used without further 
purification unless otherwise noted. Microwave reactions were performed in a single mode Biotage Initiator 
Microwave Synthesizer, and temperature was monitored using infrared. Analytical TLC was performed on pre-
coated aluminum sheets of silica (60 F 254 nm) and visualized by short-wave UV light at λ 254 nm. Melting 
points were determined on an EZ - Melt automated melting point apparatus. 1H NMR (400 MHz) and 13C NMR 
(100 MHz) spectra were recorded on a Bruker Avance II spectrometer with chemical shifts (δ) and coupling 
constants (J) expressed in ppm and Hz, respectively. The following abbreviations are used for the splitting 
patterns: s for singlet, d for doublet, t for triplet and m for multiplet. LC-MS analyses were performed using 
ESI/APCI, with an ATLANTIS C18 (50 X 4.6 mm-5µm) column and a flow rate of 1.2 mL/min. 
 
Synthesis of N-substituted derivatives 2a and 2b 
N1-cyclohexylbenzene-1,2-diamine (10 mmol, 1.0 equiv), formic acid (10 equiv) and triethyl orthoformate (1.5 
equiv) were refluxed at 100 ℃ for around 20 hours. Reaction completion was monitored by TLC. After 
completion of the reaction, the reaction mixture was distilled under reduced pressure yielding a black, oily 
crude mixture. The crude mixture was basified with saturated NaHCO3 solution and the product was extracted 
using ethyl acetate (50 mL x 2). The combined organic layers were dried using anhydrous sodium sulphate, 
distilled under vacuum, and then purified by flash column chromatography using an eluent of 20-40 % ethyl 
acetate in hexane to give the intermediates 2a and 2b.  
1-cyclohexyl-1H-benzimidazole (2a) 
Brown oil (1800 mg, 90 %). 1H NMR (400 MHz, CDCl3): H 1.27-1.29 (2H, m, CH2 cyclohexyl), 1.30-1.34 (2H, m, 
CH2 cyclohexyl), 1.91-1.94 (6H, m, 3CH2 cyclohexyl), 4.53-4.56 (1H, m, NCH cyclohexyl), 7.23-7.25 (2H, m, 2CH 
aromatic), 8.04-8.07 (1H, m, CH aromatic), 8.33-8.35 (1H, m, CH aromatic), 8.54 (1H, s, CH aromatic). LC-MS: 
201.3 (M+H). Anal. calcd for C13H16N2 (200.28): C, 77.96; H, 8.05; N, 13.99. Found: C, 78.00; H, 8.09; N, 14.03. 
1-cyclopentyl-1H-benzimidazole (2b) 
Dark brown oil (1710 mg, 92 %). 1H NMR (400 MHz, CDCl3): H 1.29-1.32 (2H, m, CH2 cyclopentyl), 1.33-1.35 
(2H, m, CH2 cyclopentyl), 1.90-1.94 (4H, m, 2CH2 cyclopentyl), 4.54-4.57 (1H, m, NCH cyclopentyl), 7.28-7.30 
(2H, m, 2CH aromatic), 8.06-8.08 (1H, m, CH aromatic), 8.35-8.37 (1H, m, CH aromatic), 8.58 (1H, s, CH 
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aromatic). LC-MS: 187.1 (M+H). Anal. calcd for C12H14N2 (186.12): C, 77.38; H, 7.58; N, 15.04. Found: C, 77.50; 
H, 7.60; N, 15.09. 
Synthesis of key intermediates 3a and 3b 
In an oven dried flask, 1-cyclohexyl-H-benzimidazole (10 mmol, 1.0 equiv) was dissolved in dry THF. The 
reaction mixture was cooled to -78 ℃ and t-butyllithium (1.7 M, 1.4 equiv) was added dropwise at -78 ℃. The 
reaction mixture was stirred for 20 minutes and N-iodosuccinimide (NIS) (1.4 equiv) was added in anhydrous 
THF dropwise at -78 ℃ and stirred for 2 hours. The progress of the reaction was monitored by TLC. After 
completion of the reaction, the reaction mixture was cooled to ambient temperature. The excess t-
butyllithium was quenched using saturated NH4Cl; excess THF was distilled off and extracted twice with ethyl 
acetate (50 mL x 2). The combined organic layers were washed with brine, dried over anhydrous sodium 
sulphate, and distilled under reduced pressure to obtain the crude mixture. The crude product was then 
purified by flash-column chromatography using 10 % ethyl acetate to give the key iodobenzimidazole 
intermediates 3a and 3b.  
1-cyclohexyl-2-iodo-1H-benzimidazole (3a) 
Yellow powder (2900 mg, 89 %). mp 106-108 ℃.1H NMR (400 MHz, CDCl3): H 1.45-1.48 (4H, m, 2CH2 
cyclohexyl), 1.89-1.92 (4H, m, 2CH2 cyclohexyl), 2.64-2.68 (2H, m, CH2 cyclohexyl), 4.41-4.44 (1H, m, NCH 
cyclohexyl), 7.22-7.25 (1H, m, CH aromatic), 7.98-8.01 (2H, m, 2CH aromatic), 8.27-8.30 (1H, m, CH aromatic). 
LC-MS: 327.2 (M+H). Anal. calcd for C13H15IN2 (326.18): C, 47.87; H, 4.64; N, 8.59. Found: C, 47.94; H, 4.70; N, 
8.63. 
1-cyclopentyl-2-iodo-1H-benzimidazole (3b) 
Yellow solid (2810 mg, 90 %). mp 103-105 ℃. 1H NMR (400 MHz, CDCl3): H 1.76-1.80 (2H, m, CH2 cyclopentyl), 
2.14-2.18 (4H, m, 2CH2 cyclopentyl), 2.58-2.61 (2H, m, CH2 cyclopentyl), 4.93-4.96 (1H, m, NCH cyclopentyl), 
7.14-7.16 (1H, m, CH aromatic), 7.93-7.95 (2H, m, 2CH aromatic), 8.26-8.28 (1H, m, CH aromatic). LC-MS 313.2 
(M+H). Anal. calcd for C12H13IN2 (312.15): C, 46.17; H, 4.20; N, 8.97. Found: C, 46.23; H, 4.28; N, 9.04. 
 
Synthesis of 2-substituted benzimidazole molecules 5(a-t) 
To the key iodobenzimidazole intermediates 3(a-b) (1 mmol, 1 equiv) in dioxane (4 mL) was added PdCl2 (5 
mol%) and SPhos (10 mol%), and the reaction mixture was degasified using nitrogen and stirred at ambient 
temperature for about 10 minutes. After 10 minutes, aryl/hetero aryl boronic acid 4(a-t) (1.6 equiv) and CsCO3 
(2 equiv) were added and the reaction mixture was again degasified for another five minutes. The reaction 
mixture was heated in microwave at 120 ℃ for 30-40 minutes. After the completion of reaction monitored by 
TLC, the reaction mixture was cooled to room temperature and 10 mL of water was added. The mixture was 
extracted using ethyl acetate and the organic layer was separated. The organic layer was dried using 
anhydrous sodium sulphate and distilled under reduced pressure to obtain the crude mixture. The crude 
product was purified by flash chromatography to afford the 2-substituted-benzimidazoles 5(a-t) in good yields. 
1-Cyclohexyl-2-(2-methoxypyrimidin-5-yl)benzimidazole (5a) 
White solid (253 mg, 82 %). mp 132-138 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.37-1.40 (2H, m, CH2 
cyclohexyl), 1.54-1.56 (4H, m, 2CH2 cyclohexyl), 2.43-2.46 (4H, m, 2CH2 cyclohexyl), 3.97-3.99 (1H, m, NCH 
cyclohexyl), 4.14 (3H, s, OCH3), 7.14 (2H, d, J 6.8 Hz, 2CH aromatic), 7.93 (2H, d, J 6.8 Hz, 2CH aromatic), 8.61 
(2H, s, 2CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 21.7 (CH2 x 2 cyclohexyl), 27.4 (CH2 cyclohexyl), 32.9 
(CH2 x 2 cyclohexyl), 52.4 (OCH3), 54.1 (NCH cyclohexyl), 106.9 (CH aromatic), 116.7 (CH aromatic), 119.3 (C 
aromatic), 121.9 (CH x 2 aromatic), 135.6 (C aromatic), 137.4 (C aromatic), 147.2 (CH x 2 aromatic), 154.7 (C 
aromatic), 166.4 (C aromatic). LC-MS (ESI-MS) m/z = 308.2 (M+1). Anal. calcd for C18H20N4O (308.16): C, 70.11; 
H, 6.54; N, 18.17. Found: C, 70.23; H, 6.61; N, 18.23. 
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1-Cyclohexyl-2-p-tolyl-benzoimidazole (5b) 
Semisolid (264 mg, 91 %). 1H NMR (400 MHz, DMSO-d6): H 1.30-1.34 (2H, m, CH2 cyclohexyl), 1.48-1.52(4H, m, 
2CH2 cyclohexyl), 2.34-2.37 (4H, m, 2CH2 cyclohexyl), 2.57 (3H, s, CH3), 3.71-3.74 (1H, m, NCH cyclohexyl), 6.99 
(2H, d, J 7.2 Hz, 2CH aromatic), 7.27 (2H, d, J 7.2 Hz, 2CH aromatic), 7.30 (2H, d, J 6.4 Hz, 2CH aromatic), 7.96 
(2H, d, J 7.6 Hz, 2CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 21.7 (CH2 x 2 cyclohexyl), 23.7 (CH3), 27.4 
(CH2 cyclohexyl), 32.9 (CH2 x 2 cyclohexyl), 54.2 (NCH cyclohexyl), 116.8 (CH aromatic), 119.3 (CH aromatic), 
122.0 (CH aromatic), 126.5 (CH aromatic), 128.9 (C aromatic), 131.5 (CH aromatic), 135.8 (CH aromatic), 137.5 
(C aromatic), 139.5 (C aromatic), 147.3 (C aromatic), 154.8 (C aromatic). LC-MS (ESI-MS) m/z = 291.4 (M+1). 
Anal. calcd for C20H22N2 (290.41): C, 82.72; H, 7.64; N, 9.65. Found: C, 82.83; H, 7.71; N, 9.68. 
1-Cyclohexyl-2-(4-methoxyphenyl)-benzimidazole (5c) 
Brown liquid (276 mg, 90 %). 1H NMR (400 MHz, DMSO-d6): H 1.34-1.37 (2H, m, CH2 cyclohexyl), 1.52-1.56 
(4H, m, 2CH2 cyclohexyl), 2.30-2.33 (4H, m, 2CH2 cyclohexyl), 3.58 (3H, s, OCH3), 3.60-3.63 (1H, m, NCH 
cyclohexyl), 6.87 (2H, d, J 6.4 Hz, 2CH aromatic), 7.20 (2H, d, J 6.4 Hz, 2CH aromatic), 7.42 (2H, d, J 7.2 Hz, 2CH 
aromatic), 7.82 (2H, d, J 7.2 Hz, 2CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 21.9 (CH2 x 2 cyclohexyl), 27.7 
(CH2 cyclohexyl), 32.9 (CH2 x 2 cyclohexyl), 52.9 (OCH3), 54.8 (NCH cyclohexyl), 115.2 (CH aromatic), 117.4 (C 
aromatic), 119.3 (CH aromatic), 121.0 (CH aromatic), 124.6 (CH aromatic), 129.4 (CH aromatic), 135.1 (CH 
aromatic), 138.4 (C aromatic), 148.9 (C aromatic), 155.5 (C aromatic), 162.1 (C aromatic). LC-MS (ESI-MS) m/z 
= 307.4 (M+1). Anal. calcd for C20H22N2O (306.41): C, 78.40; H, 7.24; N, 9.14. Found: C, 78.53; H, 7.29; N, 9.17. 
1-Cyclohexyl-2-(3-methylthiophen-2-yl)-benzimidazole (5d) 
Off-white solid (249 mg, 84 %). mp 140-145 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.26-1.29 (2H, m, CH2 
cyclohexyl), 1.62-1.65 (4H, m, 2CH2 cyclohexyl), 2.28-2.32 (4H, m, 2CH2 cyclohexyl), 3.17 (3H, s, CH3), 3.74-3.77 
(1H, m, NCH cyclohexyl), 5.64 (1H, d, J 6.0 Hz, CH aromatic), 6.68 (1H, d, J 6.4 Hz, CH aromatic), 7.20 (1H, d, J 
7.2 Hz, CH aromatic), 7.26 (1H, d, J 6.8 Hz, CH aromatic), 7.74 (1H, d, J 7.2 Hz, CH aromatic), 7.82 (1H, d, J 6.8 
Hz, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 11.2 (CH3), 21.8 (CH2 x 2 cyclohexyl), 27.3 (CH2 cyclohexyl), 
33.0 (CH2 x 2 cyclohexyl), 54.6 (NCH cyclohexyl), 116.2 (CH aromatic), 119.5 (CH aromatic), 122.0 (CH 
aromatic), 124.9 (CH aromatic), 127.1 (CH aromatic), 134.1 (CH aromatic), 135.4 (C aromatic), 137.5 (C 
aromatic), 139.2 (C aromatic), 142.9 (C aromatic), 144.1 (C aromatic). LC-MS (ESI-MS) m/z = 297.4 (M+1). Anal. 
calcd for C18H20N2S (296.43): C, 72.93; H, 6.80; N, 9.45. Found: C, 73.00; H, 6.87; N, 9.51. 
1-Cyclohexyl-2-(3-(ethylsulfonyl)phenyl)-benzimidazole (5e) 
Brown solid (321 mg, 87 %). mp 150-154 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.19 (3H, t, CH3), 1.29-1.32 (2H, 
m, CH2 cyclohexyl), 1.62-1.66 (4H, m, 2CH2 cyclohexyl), 2.51-2.54 (4H, m, 2CH2 cyclohexyl), 3.88-3.90 (2H, m, 
CH2), 3.96-3.99 (1H, m, NCH cyclohexyl), 7.17 (2H, d, J 7.6 Hz, 2CH aromatic), 7.43 (1H, d, J 7.6 Hz, CH 
aromatic), 7.69 (1H, t, CH aromatic), 7.93 (1H, d, J 7.2 Hz, CH aromatic), 7.98 (1H, d, J 7.2 Hz, CH aromatic), 
8.14 (1H, s, CH aromatic), 8.37 (1H, s, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 5.4 (CH3), 21.5 (CH2 x 2 
cyclohexyl), 27.7 (CH2 cyclohexyl), 32.6 (CH2 x 2 cyclohexyl), 52.1 (CH2), 54.7 (NCH cyclohexyl), 115.8 (CH 
aromatic), 119.9 (CH aromatic), 123.2 (CH aromatic), 124.7 (CH aromatic), 128.9 (CH aromatic), 131.4 (CH 
aromatic), 132.7 (CH aromatic), 134.0 (C aromatic), 135.3 (CH aromatic), 137.9 (C aromatic), 140.0 (C 
aromatic), 146.2 (C aromatic), 154.1 (C aromatic). LC-MS (ESI-MS) m/z = 369.5 (M+1). Anal. calcd for 
C21H24N2O2S (368.49): C, 68.45; H, 6.56; N, 7.60. Found: C, 68.64; H, 6.64; N, 7.63. 
1-Cyclohexyl-2-(3,5-difluorophenyl)-benzimidazole (5f) 
Semisolid (281 mg, 90 %). mp 158-162 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.41-1.44 (2H, m, CH2 cyclohexyl), 
1.50-1.54 (4H, m, 2CH2 cyclohexyl), 2.47-2.49 (4H, m, 2CH2 cyclohexyl), 3.80-3.83 (1H, m, NCH cyclohexyl), 6.82 
(1H, s, CH aromatic), 7.19 (1H, d, J 6.8 Hz, CH aromatic), 7.21 (1H, d, J 6.8 Hz, CH aromatic), 7.29 (2H, s, 2CH 
aromatic), 7.93 (1H, d, J 7.2 Hz, CH aromatic), 7.98 (1H, d, J 7.2 Hz, CH aromatic). 13C NMR (100 MHz, DMSO-
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d6): C 22.0 (CH2 x 2 cyclohexyl), 27.1 (CH2 cyclohexyl), 32.8 (CH2 x 2 cyclohexyl), 54.4 (NCH cyclohexyl), 104.1 
(CH aromatic), 112.2 (CH aromatic), 116.2 (CH aromatic), 119.5 (CH aromatic), 121.7 (CH aromatic), 124.1 (CH 
aromatic), 135.6 (C aromatic), 137.5 (C aromatic), 147.5 (C aromatic), 154.1 (C aromatic), 166.0 (CF aromatic). 
LC-MS (ESI-MS) m/z = 313.4 (M+1). Anal. calcd for C19H18F2N2 (312.36): C, 73.06; H, 5.81; N, 8.97. Found: C, 
73.19; H, 5.92; N, 9.01. 
1-Cyclohexyl-2-(6-methoxypyridin-3-yl)-benzimidazole (5g) 
Yellow oil (249 mg, 81 %). 1H NMR (400 MHz, DMSO-d6): H 1.38-1.40 (2H, m, CH2 cyclohexyl), 1.54-1.57 (4H, 
m, 2CH2 cyclohexyl), 2.43-2.47 (4H, m, 2CH2 cyclohexyl), 3.96-3.99 (1H, m, NCH cyclohexyl), 4.14 (3H, s, OCH3), 
6.84 (1H, d, J 6.0 Hz, CH aromatic), 7.19 (2H, d, J 6.0 Hz, 2CH aromatic), 7.96 (2H, d, J 7.6 Hz, 2CH aromatic), 
8.36 (2H, s, 2CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 21.4 (CH2 x 2 cyclohexyl), 27.0 (CH2 cyclohexyl), 
32.7 (CH2 x 2 cyclohexyl), 54.1 (NCH cyclohexyl), 56.4 (OCH3), 110.2 (CH aromatic), 116.4 (CH aromatic), 119.8 
(CH aromatic), 120.8 (C aromatic), 122.1 (CH aromatic), 122.7 (CH aromatic), 134.5 (CH aromatic), 135.4 (C 
aromatic), 140.1 (C aromatic), 141.6 (CH aromatic), 154.2 (C aromatic), 162.4 (C aromatic). LC-MS (ESI-MS) m/z 
= 308.4 (M+1). Anal. calcd for C19H21N3O (307.39): C, 74.24; H, 6.89; N, 13.67. Found: C, 74.32; H, 6.94; N, 
13.71. 
5-(1-Cyclohexyl-benzimidazol-2-yl)-N,N-dimethylpyrimidin-2-amine (5h) 
White semisolid (289 mg, 90 %). 1H NMR (400 MHz, DMSO-d6): H 1.31-1.34 (2H, m, CH2 cyclohexyl), 1.48-1.52 
(4H, m, 2CH2 cyclohexyl), 2.35-2.38 (4H, m, 2CH2 cyclohexyl), 2.51 (6H, s, 2NCH3), 3.71-3.74 (1H, m, NCH 
cyclohexyl), 7.10 (2H, d, J 7.2 Hz, 2CH aromatic), 7.83 (2H, d, J 7.2 Hz, 2CH aromatic), 8.97 (2H, s, 2CH 
aromatic). 13C NMR (100 MHz, DMSO-d6): C 21.7 (CH2 x 2 cyclohexyl), 27.4 (CH2 cyclohexyl), 32.9 (CH2 x 2 
cyclohexyl), 52.4 (NCH3 x 2), 54.2 (NCH cyclohexyl), 116.7 (CH aromatic), 119.3 (CH aromatic), 121.1 (C 
aromatic), 121.9 (CH aromatic), 135.7 (CH aromatic), 137.5 (C aromatic), 147.2 (C aromatic), 150.5 (CH 
aromatic), 154.7 (C aromatic), 162.4 (C aromatic). LC-MS (ESI-MS) m/z = 322.4 (M+1). Anal. calcd for C19H23N5 
(321.42): C, 71.00; H, 7.21; N, 21.79. Found: C, 71.13; H, 7.29; N, 21.84. 
2-(1-Benzyl-1H-pyrazol-4-yl)-1-cyclohexyl-1H-benzo[d]imidazole (5i) 
White solid (285 mg, 80 %). mp 158-160 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.38-1.40 (2H, m, CH2 
cyclohexyl), 1.54-1.58 (4H, m, 2CH2 cyclohexyl), 2.44-2.47 (4H, m, 2CH2 cyclohexyl), 3.96-3.99 (1H, m, NCH 
cyclohexyl), 5.08 (2H, s, benzylic CH2), 7.06-7.11 (5H, m, 5CH aromatic), 7.14 (2H, d, J 6.8 Hz, 2CH aromatic), 
7.21 (1H, s, CH aromatic), 7.34 (1H, s, CH aromatic), 7.93 (2H, d, J 6.8 Hz, 2CH aromatic). 13C NMR (100 MHz, 
DMSO-d6): C 21.7 (CH2 x 2 cyclohexyl), 27.4 (CH2 cyclohexyl), 32.9 (CH2 x 2 cyclohexyl), 52.4 (CH2 benzylic), 54.1 
(NCH cyclohexyl), 103.6 (C aromatic), 116.7 (CH aromatic), 119.3 (CH aromatic), 121.9 (CH aromatic), 126.1 (CH 
aromatic), 127.0 (CH aromatic), 128.1 (CH aromatic), 129.3 (CH aromatic), 130.6 (CH aromatic), 135.1 (C 
aromatic), 135.4 (CH aromatic), 137.2 (C aromatic), 144.7 (C aromatic), 155.4 (C aromatic). LC-MS (ESI-MS) m/z 
= 357.5 (M+1). Anal. calcd for C23H24N4 (356.47): C, 77.50; H, 6.79; N, 15.72. Found: C, 77.59; H, 6.94; N, 15.79. 
1-Cyclohexyl-2-(6-fluoro-5-methylpyridin-3-yl)-benzimidazole (5j) 
Pale yellow solid (266 mg, 86 %). mp 170-172 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.42-1.45 (2H, m, CH2 
cyclohexyl), 1.47-1.51 (4H, m, 2CH2 cyclohexyl), 2.30-2.34 (4H, m, 2CH2 cyclohexyl), 2.81 (3H, s, CH3), 3.79-3.82 
(1H, m, NCH cyclohexyl), 7.04 (1H, d, J 6.4 Hz, CH aromatic), 7.32 (1H, d, J 6.4 Hz, CH aromatic), 7.84 (2H, d, J 
8.0 Hz, 2CH aromatic), 8.47 (1H, s, CH aromatic), 8.87 (1H, s, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 
14.2 (CH3), 21.6 (CH2 x 2 cyclohexyl), 27.4 (CH2 cyclohexyl), 32.8 (CH2 x 2 cyclohexyl), 54.2 (NCH cyclohexyl), 
116.5 (CH aromatic), 119.3 (CH aromatic), 120.1 (C aromatic), 122.4 (CH aromatic), 129.8 (CH aromatic), 135.9 
(CH aromatic), 136.8 (C aromatic), 139.9 (C aromatic), 140.2 (CH aromatic), 147.2 (C aromatic), 154.5 (C 
aromatic), 166.4 (CF aromatic). LC-MS (ESI-MS) m/z = 310.4 (M+1). Anal. calcd for C19H20FN3 (309.38): C, 73.76; 
H, 6.52; N, 13.58. Found: C, 73.84; H, 6.63; N, 13.64. 
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2-(3,5-Bis(trifluoromethyl)phenyl)-1-cyclopentyl-1H-benzo[d]imidazole (5k) 
White solid (355 mg, 89 %). mp 183-185 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.39-1.42 (2H, m, CH2 
cyclopentyl), 1.57-1.60 (2H, m, CH2 cyclopentyl), 2.60-2.64 (4H, m, 2CH2 cyclopentyl), 3.69-3.73 (1H, m, NCH 
cyclopentyl), 6.99 (1H, s, CH aromatic) 7.29 (1H, d, J 6.8 Hz, CH aromatic), 7.31 (1H, d, J 6.8 Hz, CH aromatic), 
7.39 (2H, s, 2CH aromatic), 7.84 (1H, d, J 7.6 Hz, CH aromatic), 7.90 (1H, d, J 7.6 Hz, CH aromatic). 13C NMR 
(100 MHz, DMSO-d6): C 20.9 (CH2 x 2 cyclopentyl), 33.4 (CH2 x 2 cyclopentyl), 52.8 (NCH cyclopentyl), 115.9 
(CH aromatic), 121.1 (CH aromatic), 124.5 (CH aromatic), 126.9 (CH aromatic), 127.2 (CH aromatic), 128.9 (C 
aromatic), 130.6 (C aromatic), 132.2 (CF3 aromatic), 133.0 (C aromatic), 134.9 (C aromatic), 143.1 (C aromatic), 
155.1 (C aromatic). LC-MS (ESI-MS) m/z = 399.4 (M+1). Anal. calcd for C20H16F6N2 (398.35): C, 60.30; H, 4.05; N, 
7.03. Found: C, 60.39; H, 4.11; N, 7.07. 
2-(Benzo[d][1,3]dioxol-5-yl)-1-cyclopentyl-1H-benzo[d]imidazole (5l) 
Colorless liquid (263 mg, 86 %). 1H NMR (400 MHz, DMSO-d6): H 1.59-1.61 (2H, m, CH2 cyclopentyl), 1.98-2.01 
(4H, m, 2CH2 cyclopentyl), 2.83-2.85 (2H, m, CH2 cyclopentyl), 3.33-3.35 (1H, m, NCH cyclopentyl), 6.14 (2H, s, 
OCH2), 6.99 (1H, d, J 6.4 Hz, CH aromatic), 7.22-7.26 (3H, m, 3CH aromatic), 7.64 (2H, d, J 7.2 Hz, 2CH 
aromatic), 8.16-8.19 (1H, m, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 20.1 (CH2 x 2 cyclopentyl), 33.6 
(CH2 x 2 cyclopentyl), 56.1 (NCH cyclopentyl), 100.6 (OCH2), 112.5 (CH aromatic), 114.5 (CH aromatic), 117.1 
(CH aromatic), 119.4 (CH aromatic), 121.1 (CH aromatic), 123.6 (CH aromatic), 124.6 (CH aromatic), 125.1 (C 
aromatic), 133.1 (C aromatic), 139.1 (C aromatic), 147.2 (C aromatic), 148.2 (C aromatic), 155.6 (C aromatic). 
LC-MS (ESI-MS) m/z = 307.4 (M+1). Anal. calcd for C19H18N2O2 (306.36): C, 74.49; H, 5.92; N, 9.14. Found: C, 
74.56; H, 5.97; N, 9.16. 
4-(1-Cyclopentyl-1H-benzo[d]imidazol-2-yl)-2-fluorobenzonitrile (5m)  
Off-white solid (260 mg, 85 %). mp 189-191 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.61-1.63 (2H, m, CH2 
cyclopentyl), 1.98-2.02 (4H, m, 2CH2 cyclopentyl), 2.79-2.81 (2H, m, CH2 cyclopentyl), 3.31-3.34 (1H, m, NCH 
cyclopentyl), 7.18-7.21 (1H, m, CH aromatic), 7.68 (1H, d, J 7.6 Hz, CH aromatic), 7.86-7.89 (2H, m, 2CH 
aromatic), 8.18 (2H, d, J 7.2 Hz, 2CH aromatic), 8.21-8.23 (1H, m, CH aromatic). 13C NMR (100 MHz, DMSO-d6): 
C 23.8 (CH2 x 2 cyclopentyl), 34.1 (CH2 x 2 cyclopentyl), 56.1 (NCH cyclopentyl), 112.5 (CH aromatic), 115.9 (C 
aromatic), 116.1 (CH aromatic), 117.6 (CH aromatic), 122.3 (CN), 124.5 (CH aromatic), 132.5 (CH aromatic), 
134.2 (CH aromatic), 135.5 (C aromatic), 136.2 (CH aromatic), 139.1 (C aromatic), 144.4 (C aromatic), 159.6 (CF 
aromatic), 164.4 (C aromatic). LC-MS (ESI-MS) m/z = 306.4 (M+1). Anal. calcd for C19H16FN3 (305.35): C, 74.74; 
H, 5.28; N, 13.76. Found: C, 74.80; H, 5.30; N, 13.72.  
1-Cyclopentyl-2-(3-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazole (5n) 
White solid (312 mg, 90 %). mp 183-185 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.62-1.65 (2H, m, CH2 
cyclopentyl), 2.02-2.06 (4H, m, 2CH2 cyclopentyl), 2.70-2.73 (2H, m, CH2 cyclopentyl), 4.00-4.03 (1H, m, NCH 
cyclopentyl), 7.19-7.22 (1H, m, CH aromatic), 7.33-7.36 (1H, m, CH aromatic), 7.59-7.62 (2H, m, 2CH aromatic), 
8.10 (2H, d, J 7.2 Hz, 2CH aromatic), 8.28 (2H, d, J 7.2 Hz, 2CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 23.2 
(CH2 x 2 cyclopentyl), 35.1 (CH2 x 2 cyclopentyl), 56.2 (NCH cyclopentyl), 110.8 (CH aromatic), 113.6 (CH 
aromatic), 117.1 (CH aromatic), 119.5 (CH aromatic), 121.2 (CH aromatic), 122.6 (CH aromatic), 129.6 (CH 
aromatic), 130.1 (C aromatic), 132.6 (OCF3 aromatic), 134.2 (C aromatic), 137.1 (C aromatic), 142.9 (C 
aromatic), 155.1 (C aromatic), 160.2 (C aromatic). LC-MS (ESI-MS) m/z = 347.4 (M+1). Anal. calcd for 
C19H17F3N2O (346.35): C, 65.89; H, 4.95; N, 8.09. Found: C, 65.94, H, 4.89; N, 12.13. 
3-(1-Cyclopentyl-1H-benzo[d]imidazol-2-yl)-N,N-dimethylbenzenamine (5o) 
Brown solid (278 mg, 91 %). mp 173-175 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.60-1.63 (2H, m, CH2 
cyclopentyl), 1.97-2.01 (4H, m, 2CH2 cyclopentyl), 2.68-2.70 (2H, m, CH2 cyclopentyl), 3.11 (6H, s, 2NCH3), 4.86-
4.89 (1H, m, NCH cyclopentyl), 6.88-6.91 (1H, m, CH aromatic), 6.98 (1H, d, J 6.8 Hz, CH aromatic), 7.12 (1H, s, 
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CH aromatic), 7.30-7.33 (1H, m, CH aromatic), 7.38 (1H, t, CH aromatic), 8.09 (2H, d, J 6.8 Hz, 2CH aromatic), 
8.24-8.26 (1H, m, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 23.2 (CH2 x 2 cyclopentyl), 33.9 (CH2 x 2 
cyclopentyl), 42.4 (NCH3), 53.8 (NCH cyclopentyl), 111.7 (CH aromatic), 115.8 (CH aromatic), 116.1 (CH 
aromatic), 117.7 (CH aromatic), 119.6 (CH aromatic), 123.3 (CH aromatic), 124.2 (CH aromatic), 132.7 (C 
aromatic), 133.4 (CH aromatic), 135.2 (C aromatic), 143.1 (C aromatic), 153.3 (C aromatic), 156.1 (C aromatic). 
LC-MS (ESI-MS) m/z = 306.4 (M+1). Anal. calcd for C20H23N3 (305.42): C, 78.65; H, 7.59; N, 13.76. Found: C, 
78.69, H, 7.62; N, 13.74. 
1-Cyclopentyl-2-(1-methyl-1H-indol-5-yl)-1H-benzo[d]imidazole (5p) 
Dark brown oil (278 mg, 88 %). 1H NMR (400 MHz, DMSO-d6): H 1.65-1.68 (2H, m, CH2 cyclopentyl), 2.00-2.04 
(4H, m, 2CH2 cyclopentyl), 2.08-2.10 (2H, m, CH2 cyclopentyl), 3.67 (3H, s, NCH3), 4.92-4.95 (1H, m, NCH 
cyclopentyl), 6.68 (1H, d, J 6.0 Hz, CH aromatic), 7.16 (1H, d, J 6.0 Hz, CH aromatic), 7.28-7.30 (1H, m, CH 
aromatic), 7.47 (1H, d, J 7.2 Hz, CH aromatic), 7.63-7.65 (1H, m, CH aromatic), 7.97 (1H, s, CH aromatic), 8.10-
8.14 (2H, m, 2CH aromatic), 8.20 (1H, d, J 7.2 Hz, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 21.1 (CH2 x 2 
cyclopentyl), 34.2 (CH2 x 2 cyclopentyl), 40.2 (NCH3), 53.7 (NCH cyclopentyl), 106.2 (CH aromatic), 112.7 (CH 
aromatic), 115.3 (CH aromatic), 117.1 (CH aromatic), 120.0 (CH aromatic), 121.1 (CH aromatic), 123.6 (CH 
aromatic), 123.8 (CH aromatic), 129.6 (C aromatic), 130.1 (CH aromatic), 130.3 (C aromatic), 133.1 (C 
aromatic), 136.5 (C aromatic), 143.2 (C aromatic), 154.2 (C aromatic). LC-MS (ESI-MS) m/z = 316.4 (M+1). Anal. 
calcd for C21H21N3 (315.42): C, 79.97; H, 6.71; N, 13.32. Found: C, 80.08; H, 6.79; N, 13.37. 
2-(2-Chloro-3-methylphenyl)-1-cyclopentyl-1H-benzo[d]imidazole (5q) 
Pale yellow solid (280 mg, 90 %). mp 193-195 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.63-1.65 (2H, m, CH2 
cyclopentyl), 1.92-1.96 (4H, m, 2CH2 cyclopentyl), 2.39 (3H, s, CH3), 2.56-2.58 (2H, m, CH2 cyclopentyl), 4.43-
4.46 (1H, m, NCH cyclopentyl), 7.01-7.05 (3H, m, 3CH aromatic), 7.14 (1H, t, CH aromatic), 7.48 (2H, d, J 6.8 Hz, 
2CH aromatic), 8.00 (1H, d, J 6.8 Hz, CH aromatic). 13C NMR (100 MHz, DMSO-d6): C 16.9 (CH3), 23.6 (CH2 x 2 
cyclopentyl), 33.5 (CH2 x 2 cyclopentyl), 53.7 (NCH cyclopentyl), 112.4 (CH aromatic), 118.1 (CH aromatic), 
120.8 (CH aromatic), 121.3 (CH aromatic), 124.6 (CH aromatic), 128.0 (CH aromatic), 131.2 (CH aromatic), 
132.6 (C aromatic), 134.1 (C aromatic), 136.1 (C aromatic), 137.2 (C aromatic), 141.3 (C aromatic), 155.1 (C 
aromatic). LC-MS (ESI-MS) m/z = 311.8 (M+1). Anal. calcd for C19H19ClN2 (310.82): C, 73.42; H, 6.16; Cl, N, 9.01. 
Found: C, 73.48; H, 6.17; N, 9.00. 
5-(1-Cyclopentyl-1H-benzo[d]imidazol-2-yl)-N,N-dimethylpyrimidin-2-amine (5r) 
Colorless liquid (264 mg, 86 %). 1H NMR (400 MHz, DMSO-d6): H 1.59-1.62 (2H, m, CH2 cyclopentyl), 1.98-2.02 
(4H, m, 2CH2 cyclopentyl), 2.07-2.09 (2H, m, CH2 cyclopentyl), 2.51 (6H, s, 2NCH3), 4.43-4.46 (1H, m, NCH 
cyclopentyl), 7.11-7.15 (3H, m, 3CH aromatic), 7.21 (1H, t, CH aromatic), 8.00 (2H, s, 2CH aromatic). 13C NMR 
(100 MHz, DMSO-d6): C 22.2 (CH2 x 2 cyclopentyl), 33.4 (CH2 x 2 cyclopentyl), 42.6 (NCH3), 53.4 (NCH 
cyclopentyl), 111.3 (CH aromatic), 117.8 (CH aromatic), 121.1 (CH aromatic), 122.1 (C aromatic), 123.8 (CH 
aromatic), 135.1 (C aromatic), 142.3 (C aromatic), 148.7 (CH aromatic), 155.1 (C aromatic), 163.3 (C aromatic). 
LC-MS  (ESI-MS) m/z = 308.4 (M+1). Anal. calcd for C18H21N5 (307.40): C, 70.33; H, 6.89; N, 22.78. Found: C, 
70.38; H, 6.91; N, 22.84. 
1-Cyclopentyl-2-(2-methoxypyrimidin-5-yl)-1H-benzo[d]imidazole (5s) 
White solid (265 mg, 90 %). mp 188-190 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.38-1.40 (2H, m, CH2 
cyclopentyl), 1.54-1.58 (4H, m, 2CH2 cyclopentyl), 2.23-2.26 (2H, m, CH2 cyclopentyl), 3.92-3.95 (1H, m, NCH 
cyclopentyl), 3.98 (3H, s, OCH3), 7.14 (1H, d, J 6.4 Hz, CH aromatic), 7.18 (1H, d, J 6.4 Hz, CH aromatic), 7.93 
(1H, d, J 7.6 Hz, CH aromatic), 7.98 (1H, d, J 7.6 Hz, CH aromatic), 8.61 (2H, s, 2CH aromatic). 13C NMR (100 
MHz, DMSO-d6): C 22.2 (CH2 x 2 cyclopentyl), 33.1 (CH2 x 2 cyclopentyl), 53.1 (NCH cyclopentyl), 57.1 (OCH3), 
116.1 (CH aromatic), 119.4 (C aromatic), 120.0 (CH aromatic), 123.5 (CH aromatic), 124.2 (CH aromatic), 134.7 
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(C aromatic), 140.1 (C aromatic), 147.6 (CH aromatic), 156.2 (C aromatic), 164.1 (C aromatic). LC-MS (ESI-MS) 
m/z = 295.4 (M+1). Anal. calcd for C17H18N4O (294.35): C, 69.37; H, 6.16; N, 19.03. Found: C, 69.45; H, 6.19; N, 
19.09. 
1-Cyclopentyl-2-(3-methylthiophen-2-yl)-1H-benzo[d]imidazole (5t) 
White crystaline solid (240 mg, 85 %). mp 169-171 ℃. 1H NMR (400 MHz, DMSO-d6): H 1.36-1.39 (2H, m, CH2 
cyclopentyl), 1.58-1.60 (4H, m, 2CH2 cyclopentyl), 2.17-2.19 (2H, m, CH2 cyclopentyl), 3.31 (3H, s, CH3), 3.69-
3.72 (1H, m, NCH cyclopentyl), 5.62 (1H, d, J 5.6 Hz, CH aromatic), 6.61 (1H, t, CH aromatic), 6.89 (1H, t, CH 
aromatic), 7.21 (1H, d, J 6.8 Hz, CH aromatic), 7.60 (1H, d, J 7.2 Hz, CH aromatic), 7.72 (1H, d, J 7.2 Hz, CH 
aromatic). 13C NMR (100 MHz, DMSO-d6): C 13.6 (CH3), 22.2 (CH2 x 2 cyclopentyl), 33.6 (CH2 x 2 cyclopentyl), 
54.1 (NCH cyclopentyl), 111.5 (CH aromatic), 118.2 (CH aromatic), 123.1 (CH aromatic), 123.8 (CH aromatic), 
126.6 (CH aromatic), 127.4 (CH aromatic), 134.2 (C aromatic), 135.6 (C aromatic), 138.7 (C aromatic), 140.2 (C 
aromatic), 142.4 (C aromatic). LC-MS (ESI-MS) m/z = 283.4 (M+1). Anal. calcd for C17H18N2S (282.40): C, 72.30; 
H, 6.42; N, 9.92. Found: C, 72.36; H, 6.48; N, 9.96. 
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